drugset / Trial / NCT00932841

The Use of VSL#3 in Irritable Bowel Syndrome in Children

NCT00932841

RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to determine whether the oral administration of the probiotic VSL#3 under randomized, placebo-controlled conditions will improve symptoms of irritable bowel syndrome in children, safely.

Timeline

Start
2008-01
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator VSL#3 Other / unclassified 90 cells Oral
Comparator VSL#3 Other / unclassified 900 cells Oral